Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
ImmunityBio is a U.S.-based biotechnology company specializing in the development of innovative immunotherapies to combat cancer and infectious diseases. By leveraging advanced cell therapies and vaccine platforms, ImmunityBio aims to strengthen the body’s natural immune system to target these diseases.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
ImmunityBio is scheduled to report its next quarterly earnings on 11/05/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
ImmunityBio last reported quarterly earnings on 8/4/2026 (Q2 2026). Earnings per share (EPS) came in at -0.22 USD.
Across its last 3 earnings reports, ImmunityBio stock moved by ±7.7% on average the following day. The largest reaction was +13% on 02/23/2026; 1 of 3 reactions were positive.
ImmunityBio has beaten analyst EPS estimates in 2 of its last 5 evaluated quarters (beat rate: 40%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.